Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.
NVO - Novo Nordisk A/S
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$45.00
DETAILS
HIGH:
$45.00
LOW:
$45.00
MEDIAN:
$45.00
CONSENSUS:
$45.00
DOWNSIDE:
11.70%
Stock News
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry between the two groups.
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
With yields like this, these undervalued tickers aren't apt to remain this cheap forever.
Established Firm Harding Loevner Enters ETF Market With LOEV for International Investors
A 35-year-old institutional powerhouse just made its first move into the ETF market, betting that quality stock picking in developed markets abroad can justify a fee 23 times higher than its cheapest rival.
Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications
MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solut.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may boost demand for treatments like fillers and anti-wrinkle injections.
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Novo Nordisk (NVO) closed the most recent trading day at $48.19, moving 2.41% from the previous trading session.
Novo Resources Releases Updated Corporate Presentation
PERTH, West Australia, July 22, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company's website. The new presentation outlines Novo's strategic priorities, exploration results, project advancements, and near-term catalysts.
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the highest dose of its own weight loss drug Zepbound.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Price Targets
Novo Nordisk price target lowered to $45 from $57 at BMO Capital
$45.00
(was $47.19)
BMO Capital
Novo Nordisk (NVO) PT Raised to $57 at BMO Capital
$57.00
(was $63.80)
Evan Seigerman
·
BMO Capital
Novo Nordisk price target raised to $54 from $47 at HSBC
$54.00
(was $46.36)
HSBC
Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley
$42.00
(was $47.43)
Thibault Boutherin
·
Morgan Stanley
Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital
$46.00
(was $44.97)
Evan Seigerman
·
BMO Capital
Novo Nordisk price target raised to $55 from $50 at BMO Capital
$55.00
(was $57.50)
Evan Seigerman
·
BMO Capital
Novo Nordisk upgraded to Buy from Hold at HSBC
$70.00
(was $59.17)
HSBC
Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley
$47.00
(was $55.61)
Morgan Stanley
Novo Nordisk downgraded to Hold from Buy at HSBC
$57.00
(was $48.88)
HSBC
What's Going On With Hims & Hers Stock Wednesday?
$48.00
(was $70.03)
Jailendra Singh
·
Truist Financial
Novo Nordisk price target lowered to $156 from $160 at BMO Capital
$156.00
(was $118.58)
Evan Seigerman
·
BMO Capital
Cantor Fitzgerald on Novo Nordisk (NVO): 'These data compare favorably to other orals in development'
$160.00
(was $135.23)
Louise Chen
·
Cantor Fitzgerald
Novo Nordisk (NVO) PT Lowered to $160 at BMO Capital
$160.00
(was $126.17)
Evan David Seigerman
·
BMO Capital
Novo Nordisk price target raised to $160 from $125 at Argus
$160.00
(was $142.88)
Jasper Hellweg
·
Argus Research
Novo Nordisk initiated with a Buy at Goldman Sachs
$156.00
(was $132.68)
James Quigley
·
Goldman Sachs
BMO Capital Starts Novo Nordisk (NVO) at Outperform
$163.00
(was $125.40)
Evan David Seigerman
·
BMO Capital